Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

George Mozingo

Urology Lumberton, NC Medical Doctor

NPI 1679568067 CMS profile 894629

815 Oakridge Blvd, Lumberton, NC 28358

Open in the dashboard

General payments

$650

28 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, George Mozingo of Lumberton, NC is reported in the CMS Open Payments database as having received $650 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 26th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $175 6
2022 General $111 3
2021 General $64 3
2020 General $38 2
2019 General $262 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • George Mozingo
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to George Mozingo were reported at $0. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year George Mozingo Urology median Middle half National median
2019 $262 $480 $147–$1,201 $163
2020 $38 $246 $87–$645 $114
2021 $64 $358 $111–$1,000 $132
2022 $111 $476 $143–$1,263 $149
2023 $175 $560 $168–$1,461 $160
2024 $0 $563 $170–$1,464 $164
2025 $0 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Astellas Pharma US Inc $311 14 payments
  2. 180 Medical, Inc. $68 3 payments
  3. Teleflex LLC $58 2 payments
  4. Boston Scientific Corporation $57 3 payments
  5. ConvaTec Inc. $44 1 payment
  6. AbbVie, Inc. $36 2 payments
  7. Urogen Pharma, Inc. $27 1 payment
  8. Laborie Medical Technologies Corp. $26 1 payment
  9. Myovant Sciences Inc. $24 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $486 25 payments
  2. Education $164 3 payments
Products named General payments · program years 2019–2023
  1. MYRBETRIQ $171 12 payments
  2. GENTLECATH $65 2 payments
  3. UROLIFT $58 2 payments
  4. LUPRON DEPOT $36 2 payments
  5. General Therapies $31 1 payment
  6. JELMYTO $27 1 payment
  7. ORGOVYX $24 1 payment
  8. XTANDI $15 1 payment
  9. Obtryx System - Curved $14 1 payment
  10. rezum Generator $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,250

Median for Urology: 1,053

Drug cost

$14,174

Median for Urology: $101,464

Branded share of claims

7%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tamsulosin Hcl Generic 645 $7,625
Finasteride Generic 275 $3,318
Potassium Citrate Er Potassium Citrate Brand 19 $620
Dutasteride Generic 33 $590
Oxybutynin Chloride Generic 63 $422
Alfuzosin Hcl Er Alfuzosin Hcl Brand 22 $340
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 12 $259
Terazosin Hcl Generic 17 $196
Testosterone Cypionate Generic 21 $183
Ciprofloxacin Hcl Generic 56 $155

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$28,486

Medicare's payments for the services billed

Medicare patients

252

Average age 76

Services billed

734

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 44%
Ischemic heart disease 42%
Arthritis 41%
Chronic kidney disease 33%
Cancer 29%
Atrial fibrillation 25%
Heart failure 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record